Another company gets a better product out. Position 400 @$1.82 VYNE Earnings have increased exponentially QOQ Today they announced the execution of a contract for … https://www.globenewswire.com/news-release/2021/01/21/2162077/0/en/VYNE-Therapeutics-Announces-Contract-Execution-for-AMZEEQ-minocycline-and-ZILXI-minocycline-with-Major-Pharmacy-Benefit-Management-PBM-Company.html, https://www.globenewswire.com/news-release/2020/11/05/2120867/0/en/VYNE-Therapeutics-Reports-Third-Quarter-2020-Financial-Results-and-Provides-Business-Update.html#:~:text=Revenues%20totaled%20%2416.7%20million%20and,%2C%202020%20and%202019%2C%20respectively, https://www.marketbeat.com/stocks/NASDAQ/VYN, https://finance.yahoo.com/news/vyne-therapeutics-announces-contract-execution-130000132.html. Vyne Therapeutics. P/E of -0.8 because of negative earnings per share. FINALLY somebody started to cover this stock, I’m fairly new to Reddit for finance but I was about to write my own DD on this. Will edit message if you let me know. They are trying to destroy a very good company who is about to come out of the shadows and shine. Might not be a 10 bagger BUT usually in biotech sector the price for a company tends to around 7 times top revenues. Companies in the industry of "pharmaceutical preparations" are considered alternatives and competitors to VYNE Therapeutics, including Innoviva (INVA), Kiniksa Pharmaceuticals (KNSA), Antibe Therapeutics (ATBPD), Omeros (OMER), Arcutis Biotherapeutics (ARQT), and Epizyme (EPZM). I see this one as a long term play, but I will keep my strategy of selling half my shares if this stock ever doubles my dollar cost average. That follows a 6% rally last week. To be honest i think this one is a little too difficult for me to explain in my own words, so here is the company’s explanation of what it is: The company aims for the dermatology market. Vyne Therapeutics (NASDAQ: VYNE) Evofem Biosciences. Don't go against smart money. In fact, earlier this week, Vyne gained approval by the FDA to include new information in the product label for AMZEEQ® (minocycline). increase in cash burn and deficit could cause problems in the future if no financing can be done. It popped off right late in the after market Friday evening... popular youtuber put it on the radar for their followers. Keeping it short and sweet of why I think VYNE(VYNE Therapeutics) is an extremely good and safe bet. Lol I got in yesterday at market open for 1.96 I think that op did the same. Vyne has been on our list of penny stocks for weeks, thanks to the attention surrounding the company’s treatment pipeline. Earnings and Valuation of VYNE Therapeutics (NASDAQ:VYNE Earnings for VYNE Therapeutics are expected to grow in the coming year, from ($2.36) to ($0.44) per share. Move over GameStop, Reddit mania is spreading to the precious metals market. For some of you that do not know, VYNE therapeutics is a company that works in the innovation against acne. Annual balance sheet by MarketWatch. Not gonna write a thousand word thesis here cause nobody gonna read that. Two products are approved ( Amzeeq and Zilxi ) and a third product ( FCD105 Foam) is in phase 2 of approval. News. IPO in January 2020, dropped because covid, but surprisingly hasn’t recovered since even though prescriptions have surpassed pre-covid levels. Find real-time VYNE - Vyne Therapeutics Inc stock quotes, company profile, news and forecasts from CNN Business. VYNE Therapeutics™ is working to solve some of today’s most difficult therapeutic challenges. Mr. Domzalski holds a BA in economics and political science from Muhlenberg College, Allentown, Pennsylvania. VYNE Therapeutics, last week, announced contract execution for AMZEEQ and ZILXI with a major pharmacy benefit management company. RECAP : cash and assets increased and liabilities decreased, which is very good news. VYNE Therapeutics (VYNE) traded 438050 shares on hands in most recent trading session and observed an average volume with 6286.87K shares. David Domzalski. Press question mark to learn the rest of the keyboard shortcuts. Considering 5 billion market (pre-cream treatments, might increase) and a 15% penetration you can do the math. Was losing money until today. Furthermore, those who look at technical indicators, you’ll notice something interesting as well. (It went down after that). Investor Relations: Joyce Allaire LifeSci Advisors, LLC 646-889-1200 jallaire@lifesciadvisors.com. Covid/fears of $$ since pennystock, but altough strong balance sheet. With analyst price targets ranging from 3$ to 10$, i can’t help myself but be bullish since it is at a price of 2$ right now. This company belong to USA Country and part of Healthcare sector. Futhermore, it’s montly prescription numbers ( TRx= total prescriptions ) have been increasing a lot: Zilxi is a product that aims the rosacea problem that certain adults have. Keeping it short and sweet of why I think VYNE(VYNE Therapeutics) is an extremely good and safe bet. Hype has not engulfed this stock yet. A beneficial owner recently indirectly acquired around 4.22 million Vyne Therapeutics Inc (NASDAQ: VYNE) shares at $2.37 apiece.That totaled about $10 million and boosted the owner's stake to … VYNE Therapeutics, last week, announced contract execution for AMZEEQ and ZILXI with a major pharmacy benefit management company. Share your opinion and gain insight from other stock traders and investors. The P/E ratio of VYNE Therapeutics is -0.43, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings. Silver futures surged as much as 13% to Monday, touching five-month highs. However, this company addresses mostly acne, which is, <

Typhoon Winnie Death, Tudn Channel Antenna, Go Greek Tv, Light You Up, Olds 403 Stock Cam Specs, Belly Button Piercing Rejection,